The main reason for the limited use of NF-κB inhibitors in cancer treatments is the risk of interfering with NF-κB physiological functions, such as immune system regulation, anti-inflammatory responses, and cellular homeostasis maintenance. The gene discussed is NFKB1; the disease is cancer.